Showing 3951-3960 of 6037 results for "".
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- Analysis: Alopecia Areata Linked with Work Productivity Losseshttps://practicaldermatology.com/news/analysis-alopecia-areata-linked-with-work-productivity-losses/2462430/Results from a new real-world analysis illuminated demographic and clinical characteristics associated with productivity losses in individuals with alopecia areata. “Patients with alopecia areata experience poor health-related quality of life and significant disease burden,” the authors w
- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on t
- Long-acting Reversible Contraception Linked with Acne Young Adults: Analysishttps://practicaldermatology.com/news/relationship-between-long-acting-reversible-contraception-and-acne-in-a-cohort-of-adolescents-and-young-adults/2462264/The use of progestin-only long-acting reversible contraception (LARC) may have an increased risk of developing acne or experiencing worsening of acne symptoms, a new analysis indicates. "Few studies have focused primarily on the effects of hormonal LARC on the developmen
- Report: Unacceptably High Benzene Levels Detected in Numerous Acne Products Containing BPOhttps://practicaldermatology.com/news/report-unacceptably-high-benzene-levels-detected-in-numerous-acne-products-containing-bpo/2462262/An independent laboratory has reported that it has detected elevated levels of benzene in a number of widely used acne products, according to a press release. Valisure, an independent testing laboratory based in Connecticut, has filed a
- After Positive Phase 1 Results, Apogee to Test Twice-Yearly Dosing of Atopic Dermatitis Drug Candidatehttps://practicaldermatology.com/news/after-positive-phase-1-results-apogee-to-test-twice-yearly-dosing-of-atopic-dermatitis-drug-candidate/2462261/Apogee Therapeutics announced positive interim phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. Pharmacokinetic (PK) data showed a half-l
- Bimekizumab Not Linked with Depression, Suicidal Ideation in Moderate-to-Severe Psoriasishttps://practicaldermatology.com/news/mental-health-outcomes-in-patients-with-moderate-to-severe-psoriasis-treated-with-bimekizumab-analysis-of-phase-23-randomized-trials/2462260/A new analysis indicates that bimekizumab was not associated with a high risk of suicidal ideation/behavior (SIB) and depression. Psoriasis patients often face increased risks of SIB and depression, according to the researchers. Bimekizumab, an FDA-approved biologic inhibiting
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- Nutrafol® Announces Expansion Into Skin with Daily Acne Supplementhttps://practicaldermatology.com/news/hair-health-leader-nutrafol-expands-into-skin/2462253/Hair health leader Nutrafol has announced an expansion into the skin space with the launch of its new product, Nutrafol Skin. According to the manufacturer, the first-of-its-kind once-daily supplement for women 18 years of age and older who experience mild to moderate acne. A
- Alvotech and Teva Announce US Approval of Simlandi, a Biosimilar to Humirahttps://practicaldermatology.com/news/alvotech-and-teva-announce-us-approval-of-simlandi-a-biosimilar-to-humira/2462250/Alvotech and Teva Pharmaceuticals announced the FDA approval of Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to blockbuster drug Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as&n